

Table 1. Characteristic of the total cohort and the study population matched on propensity score for patients with therapeutic anticoagulation use and unexposed patients.

Characteristic	Total cohort					Propensity score-matched cohort						
	Therapeutic		No therapeutic		P-value	St. Diff.*	Therapeutic		No therapeutic		P-value	St. Diff.*
	AC use (N=190)		AC use (N=964)				AC use (N=164)		AC use (N=410)			
	n	(%)	n	(%)			n	(%)	n	(%)		
Age, median (IQR), y	76	(72-82)	68	(57-76)	<0.001	0.89	76	(71-82)	76	(70-82)	0.70	0.035
Females	55	(29)	364	(38)	0.02	0.19	53	(32)	132	(32)	0.98	0.0026
BMI, median (IQR), kg/m ²	27.6	(24.0-31.1)	27.6	(25.0-30.8)	0.73	0.03	27.6	(24.4-31.7)	27.7	(24.8-30.8)	0.91	0.010
Cardiovascular disease												
Hypertension	112	(59)	341	(35)	<0.001	0.49	96	(58)	213	(52)	0.15	0.13
Obstructive CAD	52	(27)	96	(10)	<0.001	0.46	42	(26)	83	(20)	0.16	0.13
Myocardial infarction	30	(16)	80	(8)	<0.001	0.23	22	(13)	59	(14)	0.76	0.028
Heart failure	40	(21)	17	(2)	<0.001	0.64	17	(10)	17	(4)	0.004	0.24
Nonischaemic cardiomyopathy	12	(6)	15	(2)	<0.001	0.25	8	(5)	14	(3)	0.41	0.073
Previous heart surgery	18	(9)	25	(3)	<0.001	0.29	13	(8)	24	(6)	0.36	0.082
Electronic heart device	13	(7)	12	(12)	<0.001	0.29	7	(4)	11	(3)	0.33	0.086
CVA	37	(19)	99	(10)	<0.001	0.26	34	(21)	73	(18)	0.42	0.074
Peripheral artery disease	20	(11)	41	(4)	<0.001	0.24	18	(11)	33	(8)	0.27	0.10
Diabetes mellitus	52	(27)	210	(22)	0.09	0.13	47	(29)	110	(27)	0.66	0.041
Chronic pulmonary disease	53	(28)	225	(23)	0.18	0.10	43	(26)	107	(26)	0.98	0.0028
Active malignancy	43	(23)	169	(18)	0.10	0.13	38	(23)	91	(22)	0.80	0.023
Immunosuppressant use	23	(12)	102	(11)	0.54	0.05	19	(12)	55	(13)	0.56	0.055
No ICU policy	114	(60)	268	(28)	<0.001	0.69	92	(56)	218	(53)	0.53	0.059

AC, anticoagulation; CAD,coronary artery disease; CVA,cerebrovascular accident; ICU, intensive care unit; IQR, interquartile range

* Standardized differences to compare the distribution of covariates between the exposure groups.